See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The duration of effect of Cosentyx can vary depending on the individual and the specific condition being treated.

In clinical studies, Cosentyx has been shown to provide significant symptom relief and improvement in physical function for up to 52 weeks in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis [2][3][4]. Additionally, some studies have suggested that the medication may continue to provide benefits for up to 3 years or more in certain patients [5].

It is important to note that the duration of effect of Cosentyx can vary depending on several factors, including the individual's response to the medication, the severity of the condition being treated, and the presence of any other underlying medical conditions. Additionally, it is important to follow the recommended dosage and administration schedule for Cosentyx as prescribed by a healthcare professional.

In summary, Cosentyx has been shown to provide significant symptom relief and improvement in physical function for up to 52 weeks in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis. Some studies have suggested that the medication may continue to provide benefits for up to 3 years or more in certain patients. However, the duration of effect of Cosentyx can vary depending on several factors, and it is important to follow the recommended dosage and administration schedule as prescribed by a healthcare professional.

Sources:

* [1] <https://www.cosentyx.com/about-cosentyx/what-is-cosentyx>
* [2] "Efficacy and Safety of Secukinumab in Psoriasis: A 52-Week, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study (SCULPTURE)." National Center for Biotechnology Information, U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/25823152.
* [3] "Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, in Patients with Active Psoriatic Arthritis: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial." National Center for Biotechnology Information, U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/26032135.
* [4] "Secukinumab, a Human Anti–Interleukin-17A Monoclonal Antibody, in Ankylosing Spondylitis." National Center for Biotechnology Information, U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/26282368.
* [5] "Secukinumab Provides Sustained Improvements in Signs and Symptoms of Psoriasis Through 3 Years: Results from an Open-Label Extension of a Phase 3, Randomized, Placebo-Controlled Trial (SCULPTURE)." National Center for Biotechnology Information, U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/pubmed/28801651.